Drug Type Small molecule drug |
Synonyms SFA 005 |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization SFA Therapeutics, Inc.Startup |
Active Organization SFA Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Preclinical | US | SFA Therapeutics, Inc.Startup | 01 Dec 2024 |
Chronic Myelogenous Leukemia | Preclinical | US | SFA Therapeutics, Inc.Startup | 01 Dec 2024 |
Uveitis | Preclinical | US | SFA Therapeutics, Inc.Startup | 01 Dec 2024 |
SARS-CoV-2 acute respiratory disease | Preclinical | US | SFA Therapeutics, Inc.Startup | 09 May 2020 |